136 related articles for article (PubMed ID: 38483122)
1. Expanding MELD exceptions for colorectal liver metastasis: data and policy.
Whitrock JN; Pratt CG; Shah SA
Curr Opin Organ Transplant; 2024 Jun; 29(3):195-199. PubMed ID: 38483122
[TBL] [Abstract][Full Text] [Related]
2. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
4. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
Nobel YR; Goldberg DS
Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
[TBL] [Abstract][Full Text] [Related]
5. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States.
Kubal C; Mihaylov P; Holden J
Curr Opin Organ Transplant; 2021 Apr; 26(2):168-175. PubMed ID: 33650998
[TBL] [Abstract][Full Text] [Related]
6. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
[TBL] [Abstract][Full Text] [Related]
7. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
8. Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant.
Merola J; Gan G; Stewart D; Noreen S; Mulligan D; Batra R; Haakinson D; Deng Y; Kulkarni S
PLoS One; 2021; 16(11):e0260000. PubMed ID: 34793524
[TBL] [Abstract][Full Text] [Related]
9. Auxiliary living donor liver transplantation combined with two-stage hepatectomy for unresectable colorectal liver metastases.
Nadalin S; Königsrainer A; Capobianco I; Settmacher U; Rauchfuss F
Curr Opin Organ Transplant; 2019 Oct; 24(5):651-658. PubMed ID: 31397729
[TBL] [Abstract][Full Text] [Related]
10. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
11. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
[TBL] [Abstract][Full Text] [Related]
12. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
[TBL] [Abstract][Full Text] [Related]
13. The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality.
Dirchwolf M; Becchetti C; Gschwend SG; Toso C; Dutkowski P; Immer F; Beyeler F; Rossi S; Schropp J; Dufour JF; Banz V;
HPB (Oxford); 2022 Jul; 24(7):1168-1176. PubMed ID: 35065891
[TBL] [Abstract][Full Text] [Related]
14. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
Trotter JF; Osgood MJ
JAMA; 2004 Apr; 291(15):1871-4. PubMed ID: 15100206
[TBL] [Abstract][Full Text] [Related]
15. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.
Francoz C; Belghiti J; Castaing D; Chazouillères O; Duclos-Vallée JC; Duvoux C; Lerut J; Le Treut YP; Moreau R; Mandot A; Pageaux G; Samuel D; Thabut D; Valla D; Durand F
Liver Transpl; 2011 Oct; 17(10):1137-51. PubMed ID: 21695771
[TBL] [Abstract][Full Text] [Related]
16. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
Zendel A; Watkins R; Moon AM; Gerber DA; Barritt AS; Desai CS
Clin Transplant; 2022 May; 36(5):e14609. PubMed ID: 35137467
[TBL] [Abstract][Full Text] [Related]
17. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
[TBL] [Abstract][Full Text] [Related]
18. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
19. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.
Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM
Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794
[TBL] [Abstract][Full Text] [Related]
20. Should All Status 1A Patients Be Prioritized Over High MELD Patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients.
Safwan M; Nwagu U; Collins K; Abouljoud M; Nagai S
Transplantation; 2019 Oct; 103(10):2121-2129. PubMed ID: 30747840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
